Inovio Pharmaceuticals, Inc. (INO) financial statements (2021 and earlier)

Company profile

Business Address 6769 MESA RIDGE RD.
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:4123373722709094106
Cash and cash equivalents251179215158221620
Short-term investments161159156112677886
Other undisclosed cash, cash equivalents, and short-term investments(0)(0)00(0)00
Receivables19841221
Prepaid expense5      
Other undisclosed current assets363264333
Total current assets:4713773822769499111
Noncurrent Assets
Operating lease, right-of-use asset13131314141414
Property, plant and equipment11111112131414
Long-term investments and receivables01321   
Long-term investments01321   
Intangible assets, net (including goodwill)14141414141415
Goodwill11111111111111
Intangible assets, net (excluding goodwill)3334444
Other noncurrent assets261832333
Other undisclosed noncurrent assets44170688
Total noncurrent assets:69616163505355
TOTAL ASSETS:540438443339144152165
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:21241711181013
Accrued liabilities     55
Employee-related liabilities13   9  
Other undisclosed accounts payable and accrued liabilities8241711959
Deferred revenue0000000
Debt   2222
Due to related parties1110101
Other undisclosed current liabilities201720191178
Total current liabilities:42413832322024
Noncurrent Liabilities
Long-term debt and lease obligation18191920202121
Operating lease, liability18191920202121
Liabilities, other than long-term debt0000900
Deferred revenue0000000
Deferred income tax liabilities0000000
Other liabilities0000000
Derivative instruments and hedges, liabilities    9  
Other undisclosed noncurrent liabilities195419999777563
Total noncurrent liabilities:37732191191079685
Total liabilities:79114257151139115109
Stockholders' equity
Stockholders' equity attributable to parent46132418618433454
Common stock0000000
Additional paid in capital1,3671,2061,088958743735732
Accumulated other comprehensive income (loss)(0)(0)(1)(1)011
Accumulated deficit(906)(882)(901)(772)(740)(702)(679)
Stockholders' equity attributable to noncontrolling interest 004223
Total stockholders' equity:46132418618853656
TOTAL LIABILITIES AND EQUITY:540438443339144152165

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Gain on disposition of assets for financial service operations     0 
Net investment income 110 11
Gross profit:5111011
Operating expenses(35)(37)(33)(27)(31)(25)(28)
Other undisclosed operating income (loss)1(1)(1)   (1)
Operating loss:(29)(36)(33)(25)(30)(24)(28)
Nonoperating income (expense)0(0)4(0)000
Investment income, nonoperating  4    
Other nonoperating income (expense)0(0)(0)(0)000
Interest and debt expense(1)(2)(3)(3)(3)(2)(2)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes4259(96)    
Income (loss) from continuing operations before equity method investments, income taxes:1121(128)(28)(33)(26)(30)
Income (loss) from equity method investments3(2)(1)    
Other undisclosed income (loss) from continuing operations before income taxes(34)  (5)(5)31
Income (loss) from continuing operations before income taxes:(20)19(129)(33)(38)(24)(30)
Income tax benefit    0 0
Income (loss) before gain (loss) on sale of properties:(20)19(129)(33)(38)(24)(30)
Other undisclosed net loss(5)      
Net income (loss):(24)19(129)(33)(38)(24)(30)
Net income attributable to noncontrolling interest  01000
Net income (loss) available to common stockholders, basic:(24)19(129)(33)(38)(23)(29)
Dilutive securities, effect on basic earnings per share     (2) 
Net income (loss) available to common stockholders, diluted:(24)19(129)(33)(38)(25)(29)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net income (loss):(24)19(129)(33)(38)(24)(30)
Other comprehensive income    1  
Other undisclosed comprehensive income (loss)(0)01(2)(1)(0)0
Comprehensive income (loss):(24)20(128)(35)(38)(24)(29)
Comprehensive income, net of tax, attributable to noncontrolling interest  01000
Comprehensive income (loss), net of tax, attributable to parent:(24)20(128)(34)(38)(23)(29)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: